Skip to main content

Table 1 Overview of radionuclides and corresponding ligands used in this study

From: 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617

Nuclide

Half-life

Radiation energy

Ligand

Chelator

Application

Refs.

44Sc

4.04 h

+ av = 632 keV

Eγ = 1157 keV*

PSMA-617

DOTA

PET

+-radiation)

Evaluated in this study

177Lu

6.65 days

av = 134 keV

Eγ = 113 keV, 208 keV

PSMA-617

DOTA

Therapy/SPECT

/γ-radiation)

[22, 3739]

68Ga

68 min

+ av = 830 keV

Eγ = 1077 keV**

PSMA-617

PSMA-11

DOTA

HBED-CC

PET

+-radiation)

[21]

[17, 18, 40]

  1. *I = 99.9%; **I = 3.2%